Financhill
Sell
48

ASND Quote, Financials, Valuation and Earnings

Last price:
$212.84
Seasonality move :
19.56%
Day range:
$210.20 - $216.19
52-week range:
$118.03 - $229.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.80x
P/B ratio:
--
Volume:
386.1K
Avg. volume:
772.7K
1-year change:
53.33%
Market cap:
$13B
Revenue:
$393.3M
EPS (TTM):
-$4.25

Earnings Data

Next earnings date for ASND
Feb 11
2026
Most recent earnings per share
-$1.17
Missed by $0.99
(Nov 12/2025)
Consensus Estimate
-$0.18
(Nov 12/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

ASND Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
02/11/2026 Q4 $288.9M -- -- -$0.17 --
11/12/2025 Q3 $245M $249.6M -$1.17 -$0.18 -$0.99
08/07/2025 Q2 $166.8M $179.3M -$0.73 -$1.52 $0.79
05/01/2025 Q1 $107.9M $106.3M -$1.66 -$1.71 $0.06
02/12/2025 Q4 $123.2M $185.5M -$0.69 -$0.96 $0.28
11/14/2024 Q3 $76.5M $63.5M -$1.89 -$1.57 -$0.32
09/03/2024 Q2 $94.2M $38.8M -$2.06 -$1.40 -$0.65
05/02/2024 Q1 $85.6M $104.2M -$2.50 -$1.52 -$0.98
02/07/2024 Q4 $92.1M $148.3M -$1.66 -$1.90 $0.24
11/07/2023 Q3 -- -- -$3.14 -$2.37 -$0.76
09/05/2023 Q2 -- -- -$2.36 -$2.80 $0.45
04/27/2023 Q1 -- -- -$2.13 -$2.89 $0.77
02/16/2023 Q4 -- -- -$3.78 -$2.77 -$1.02
11/02/2022 Q3 -- -- -$3.05 -$2.52 -$0.53
08/10/2022 Q2 -- -- -$1.56 -$2.28 $0.73
05/11/2022 Q1 -- -- -$2.48 -$2.15 -$0.33
03/02/2022 Q4 -- -- -$2.14 -$2.59 $0.46
11/10/2021 Q3 -- -- -- -$2.66 --
08/25/2021 Q2 -- -- -$3.01 -$2.64 -$0.37
05/27/2021 Q1 -- -- -$1.41 -$2.27 $0.86
03/10/2021 Q4 -- -- -$3.15 -$1.88 -$1.27
11/11/2020 Q3 -- -- -$2.70 -$1.87 -$0.83
08/27/2020 Q2 -- -- -$2.17 -$1.60 -$0.57
05/19/2020 Q1 -- -- -$1.46 -$1.40 -$0.05
12/31/2019 Q4 -- -- -$1.88 -$1.32 -$0.56
11/18/2019 Q3 -- -- -$0.59 -$1.28 $0.69
08/28/2019 Q2 -- -- -- -$1.33 --
04/03/2019 Q1 -- -- -- -$1.14 --
12/31/2018 Q4 -- -- -- -$1.13 --
11/28/2018 Q3 -- -- -- -$1.20 --
08/29/2018 Q2 -- -- -- -$0.99 --
05/30/2018 Q1 -- -- -- -- --
03/28/2018 Q4 -- -- -- -- --
11/16/2017 Q3 -- -- -- -- --
08/18/2017 Q2 -- -- -- -- --
03/31/2017 Q1 -- -- -- -- --
12/31/2016 Q4 -- -- -- -- --
11/30/2016 Q3 -- -- -- -- --
08/31/2016 Q2 -- -- -- -- --
03/31/2016 Q1 -- -- -- -- --
12/31/2015 Q4 -- -- -- -- --

Ascendis Pharma A/S Earnings Questions

  • How Much did Ascendis Pharma A/S Generate in Revenue Last Quarter?

    Ascendis Pharma A/S reported $249.6M worth of top line sales in its most recent quarter.

  • Did Ascendis Pharma A/S Beat Earnings Last Quarter?

    Ascendis Pharma A/S announced earnings per share of -$1.17 which represents a miss of analyst forecast a -$0.18 per share.

  • Is Ascendis Pharma A/S Profitable?

    Ascendis Pharma A/S reported $219.4M that represents $3.61 per share over the last quarter.

  • What is the Analyst Consensus for Ascendis Pharma A/S EPS Next Year?

    Ascendis Pharma A/S's earnings are forecast to decrease from -$7.06 per share to -$6.78 per share next year representing a decrease of -46.48%.

  • When is Ascendis Pharma A/S's Earnings Date?

    Ascendis Pharma A/S's next earnings date is February 11, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
85
HUT alert for Dec 25

Hut 8 Corp. [HUT] is up 0.65% over the past day.

Buy
80
TVTX alert for Dec 25

Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.

Buy
63
GPCR alert for Dec 25

Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock